The Combination of Sofosbuvir and Simeprevir Compared to Sofosbuvir and Ribavirin in Patients With Hepatitis C–Related Child’s Class A Cirrhosis
Mina Emil Fouad Antoun;
Abstract
According to the World Health Organization, there are about 130-150 million people chronically infected with hepatitis C virus (HCV). The 2015 Egypt Health Issues Survey (EHIS) by Ministry of Health and Population revealed that 6% of individuals aging 1-59 years had a positive hepatitis C antibody test.
Chronic HCV results in liver injury that may lead to fibrosis. Once cirrhosis is established, HCC develops at an annual rate of 1% to 4%
Six treatment options are available in EASL 2015 recommendations for patients infected with HCV genotype 4. We investigated the efficacy of combined simeprevir/ sofosbuvir for 12 weeks versus Sofosbuvir/Ribavirin for 24 weeks.
In the current study, 90 patients were assigned in two groups, group-A and group-B. Group A included 50 patients who received sofosbuvir 400 mg plus simeprevir 150 mg for 12 weeks. Group B included 40 patients who received sofosbuvir 400 mg plus ribavirin (according to body weight: 1000 mg daily in patients with a body weight of <75 kg and1200 mg) for 24 weeks. All enrolled patients had compensated cirrhosis at time of enrollment. The presence of cirrhosis was determined on the basis of fibro-scan test (All patients were F4 according to METAVIR scoring system). All were Child A according to Child –Turcotte Pugh scoring system. The primary endpoint was sustained virological response 12 weeks after stopping treatment (SVR12).
In this study, SVR was achieved by 90% in Sofosbuvir/Simeprevir regimen and 77% in Sofosbuvir/ Ribavirin regimen with recurrence rate of 8.2% in Sofosbuvir/ Simeprevir regimen and 18.4% in Sofosbuvir/ Ribavirin regimen.
Also, results showed that smoking was less frequent among responders than among non-responders, but the differences were significant only in Sofosbuvir/Simeprevir regimen.
In conclusion, Combined Sofosbuvir/Simeprevir was more efficacious than Sofosbuvir/Ribavirin. cigarette smoking decreases the treatment response to antiviral treatment.
Chronic HCV results in liver injury that may lead to fibrosis. Once cirrhosis is established, HCC develops at an annual rate of 1% to 4%
Six treatment options are available in EASL 2015 recommendations for patients infected with HCV genotype 4. We investigated the efficacy of combined simeprevir/ sofosbuvir for 12 weeks versus Sofosbuvir/Ribavirin for 24 weeks.
In the current study, 90 patients were assigned in two groups, group-A and group-B. Group A included 50 patients who received sofosbuvir 400 mg plus simeprevir 150 mg for 12 weeks. Group B included 40 patients who received sofosbuvir 400 mg plus ribavirin (according to body weight: 1000 mg daily in patients with a body weight of <75 kg and1200 mg) for 24 weeks. All enrolled patients had compensated cirrhosis at time of enrollment. The presence of cirrhosis was determined on the basis of fibro-scan test (All patients were F4 according to METAVIR scoring system). All were Child A according to Child –Turcotte Pugh scoring system. The primary endpoint was sustained virological response 12 weeks after stopping treatment (SVR12).
In this study, SVR was achieved by 90% in Sofosbuvir/Simeprevir regimen and 77% in Sofosbuvir/ Ribavirin regimen with recurrence rate of 8.2% in Sofosbuvir/ Simeprevir regimen and 18.4% in Sofosbuvir/ Ribavirin regimen.
Also, results showed that smoking was less frequent among responders than among non-responders, but the differences were significant only in Sofosbuvir/Simeprevir regimen.
In conclusion, Combined Sofosbuvir/Simeprevir was more efficacious than Sofosbuvir/Ribavirin. cigarette smoking decreases the treatment response to antiviral treatment.
Other data
| Title | The Combination of Sofosbuvir and Simeprevir Compared to Sofosbuvir and Ribavirin in Patients With Hepatitis C–Related Child’s Class A Cirrhosis | Other Titles | مقارنة بروتوكول علاج سوفوسبوفير وسيمبريفير مع سوفوسبوفير وريبافيرين في المرضى المصابين بإلتهاب الكبدي الوبائي "سي" ذات فئة تليف (تشيلد "أ") | Authors | Mina Emil Fouad Antoun | Issue Date | 2016 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.